Veracyte (VCYT) Guggenheim Inaugural Global Healthcare Innovation Conference summary

Conference highlights

• Positive feedback received after a strong quarterly performance, with revenue and P&L beats and higher-than-expected 2025 Afirma revenue guidance.

• Continued outperformance of Decipher and strong execution across revenue growth drivers.

• 2024 Adjusted EBITDA margins guided at approximately 20%, with incremental expansion expected in 2025.

• Focus on setting realistic 2025 guidance, with budgeting to be finalized soon and public discussion planned for early January.

• Emphasis on long-term growth drivers and consistent execution.

Product and market updates

• Afirma growth driven by innovation, new features, and favorable comparative publications; high single-digit growth expected to continue.

• Decipher's growth supported by NCCN Level 1B guidelines, with majority of growth from existing customers expanding use across risk categories.

• Decipher market penetration was 35% at end of 2023, with share gains continuing in 2024; long-term class penetration target is around 80%.

• Decipher metastatic LCD finalized in August; broader rollout expected in Q2 2025 after tech assessment and sales team training.

• Afirma's Medicare coverage for Bethesda V is a recent tailwind, with early penetration and commercial payer discussions ongoing.

Strategic initiatives and future outlook

• IVD business is transitioning Prosigna from nCounter to NGS in 2025, with long-term growth expected from global expansion.

• C2i Genomics acquisition brought MRD and AI capabilities; integration is progressing well, with a muscle-invasive bladder cancer test launch targeted for H1 2026.

• MRD market seen as large and competitive; strategy focuses on whole genome sequencing to differentiate and address IP challenges.

• Cost of goods for MRD expected to be higher, but offset by lower R&D and S&M expenses, aiming for attractive Adjusted EBITDA at scale.

• Capital allocation prioritizes organic growth, with selective M&A and milestone payments planned for 2025.